Issue 4, 2013

Design of symmetrical and nonsymmetrical N,N-dimethylaminopyridine derivatives as highly potent choline kinase alpha inhibitors

Abstract

Choline kinase alpha is hyperactivated in many solid tumours and regulates malignant progression, making it a promising cancer drug target. The successful design and synthesis of novel inhibitors with high cellular activity are described.

Graphical abstract: Design of symmetrical and nonsymmetrical N,N-dimethylaminopyridine derivatives as highly potent choline kinase alpha inhibitors

Supplementary files

Article information

Article type
Concise Article
Submitted
28 Feb 2013
Accepted
01 Mar 2013
First published
06 Mar 2013

Med. Chem. Commun., 2013,4, 693-696

Design of symmetrical and nonsymmetrical N,N-dimethylaminopyridine derivatives as highly potent choline kinase alpha inhibitors

S. Trousil, L. Carroll, A. Kalusa, O. Aberg, M. Kaliszczak and E. O. Aboagye, Med. Chem. Commun., 2013, 4, 693 DOI: 10.1039/C3MD00068K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements